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Drug-induced gingival overgrowth (DIGO) is an adverse drug reaction mainly described with 
three types of commonly prescribed drugs, namely, calcium channel blockers (CCBs) (nifedipine, 
diltiazem, and verapamil), anti-convulsants (phenytoin), and immunosuppressive agents (cy-
closporine). Numerous reports have associated gingival overgrowth with the newer generation 
of immunosuppressive agents (tacrolimus, sirolimus, and everolimus), and CCBs (amlodipine, 
felodipine, nicardipine, and manidipine). Especially, patients concomitantly medicated with an 
immunosuppressive agent and CCB have a higher DIGO chance. Dentists need to be aware of 
drugs that induce gingival overgrowth, the possibility of DIGO, and risk factors, and also pre-
vent the progression of DIGO by early detection of DIGO, consultation about the drug change, 
and the maintenance of strict dental hygiene regimes.
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INTRODUCTION
Drug-induced gingival overgrowth (DIGO) is a noted side 
effect of three types of commonly prescribed drugs, namely, 
calcium channel blockers (CCBs) (nifedipine, diltiazem, and 
verapamil), anticonvulsants (phenytoin), and immunosup-
pressive agents (cyclosporine). Among three categories, it 
has been reported that newer generation of drugs are also 
induced gingival overgrowth. The drug categories and rep-
resentative drugs including the newer drugs are listed in 
Table 1.1-5)
Ellis et al.6) discussed the overall prevalence of gingival 
overgrowth related to chronic medication with CCBs, ad-
dressing it is considerably lower than finding from previous 
studies. Therefore, the expression of this effect needs cofac-
tors such as the presence of gingival inflammation or con-
comitant medications inducing gingival overgrowth. 
Cyclosporine has become the foundations of immuno-
suppressive therapy since the early 1980s, and tacrolimus, 
another calcineurin inhibitor, drastically decreased acute 
rejection rates since the early 1990s.7) A contradiction of 
posttransplantation care is that many of the immunosup-
pressants, especially calcineurin inhibitors, used to prevent 
allograft rejection may have serious long-term outcomes 
on the transplanted tissue and other organ systems such as 
nephrotoxic, hyperlipidemic, hypertensive, and, to some ex-
tent, neurotoxic and hepatotoxic effects.8) The use of siro-
limus, an inhibitor of the mammalian target of rapamycin, 
seems to reduce the risk for acute rejection and chronic al-
lograft nephropathy.9)
Gingival overgrowth is another recognized side effect of 
immunosuppressive therapy. DIGO is characterized by an 
increase of gingival volume usually in the gingival papil-
lae without extending beyond the mucogingival junction.10) 
Because hypertension and nephrotoxicity, adverse effects of 
cyclosporine, are often treated with CCBs, DIGO is increased 
under regimens of the combination of cyclosporine and 
CCB. Cota et al.11) discussed that the prevalence and severity 
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Table 1. Drug-induced gingival overgrowth-inducing drugs
Drug category Anti-convulsants Immunosuppressive agents Calcium channel blockers
Drugs Phenytoin
Carbamazepine
Valproic acid
Phenobarbitone
Vigabatrin
Cyclosporine
Azathioprine 
Mycophenolate mofetil
Tacrolimus
Sirolimus
Everolimus
Amlodipine
Nifedipine
Felodipine
Nitrendipine
Verapamil
Diltiazem
Nicardipine
Nisoldipine
Oxodipine
of gingival overgrowth are higher within immunosuppres-
sive regimens based on cyclosporine compared with tacro-
limus and sirolimus, and higher within immunosuppres-
sive regimens based to tacrolimus compared with sirolimus. 
Although the gingival overgrowth under sirolimus-based 
immunosuppressive regimens is not clinically significant, it 
was strongly associated with the concomitant CCB use and 
the interaction between time since transplant and previous 
calcineurin use.
 This report reviews a case of a 50-year-old man with 
DIGO related to immunosuppressants and CCBs. 
CASE REPORT
A 50-year-old male presented with generalized gingi-
val overgrowth in the keratinized gingiva which developed 
4.5 years prior to his first visit to the clinic. His chief com-
plaint was swollen feeling on the lower left posterior gin-
giva, and the lower left first and second molar showed no 
abnormality during clinical examination in the Department 
of Conservative Dentistry.
The patient had a history of kidney transplant and 
had been taking with cyclosporine for about 3.5 years. 
Cyclosporine was changed to sirolimus about 6 years ago. 
Furthermore, the patient had been taking felodipine for the 
treatment of hypertension for 9.5 years.
Gingivectomy on the upper anterior gingiva was per-
formed in the Department of Periodontology about 4 years 
prior to his first visit (Fig. 1), and the gingival overgrowth 
relapsed. At first visit, clinical examination revealed gingi-
val overgrowth and inflammation on the lower left second 
molar (Fig. 2) and the upper and lower anterior gingiva 
(Fig. 3). Generalized alveolar bone loss was observed on the 
panoramic radiograph (Fig. 4). After oral hygiene instruc-
tion was given and chlorhexidine gargle was prescribed to 
reduce the gingival inflammation, he was sent to periodon-
tist for supportive periodontal therapy.
Scaling and minocycline application were done. Two 
A B
Fig. 1. Generalized gingival overgrowth before gingivectomy procedure (A) and after gingivectomy procedure (B) about 4 years prior to first 
visit.
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months after first visit, gingival inflammation was reduced, 
but gingival overgrowth persisted (Fig. 5).
DISCUSSION
Gingival overgrowth has been associated with the admin-
istration of immunosuppressant, anticonvulsant, and CCB. 
A unifying hypothesis of these drugs side effect has been 
constructed which included the following: 1) bacterial in-
flammation increasing connective tissue production, 2) in-
ducing drugs causation of fibroblast proliferation and/or 
increased production of connective tissue, and 3) decreased 
cellular folate uptake within gingival fibroblasts by possible 
inhibitory effects upon cation channels.1)
The treatment options for DIGO should be based on the 
medication being used and the clinical presentation of 
each particular case. Firstly, treatment choices of DIGO that 
should be decided with the patient’s physician include dis-
continuing or replacing the gingival overgrowth-inducing 
drugs before gingival overgrowth aggravated. Gingivectomy 
is needed in advanced gingival overgrowth. Alternative 
medications to cyclosporine include tacrolimus or sirolim-
us that has much lower prevalence of gingival overgrowth 
than cyclosporine. Previous studies showed that prevalence 
of gingival overgrowth was 60.0%-61.0% for cyclosporine, 
26.5%-28.9% for tacrolimus, and 15.6%-20.8% for siroli-
mus groups in renal transplant recipients, though pharma-
cological and periodontal variables should be considered 
in different immunosuppressive regimens.4,11,12) Within the 
group under sirolimus-based immunosuppressive regimens, 
gingival overgrowth was associated with previous use of 
cyclosporine and concomitant CCB use.11) This interaction 
may reflect the longer exposure to cyclosporine in previous 
immunosuppressive regimens and may indicate that gin-
gival alterations are a residual effect of past cyclosporine 
Fig. 2. Gingival overgrowth and inflammation on the lower left 
second molar.
A B
Fig. 3. Gingival overgrowth on the upper (A) and the lower (B) anterior teeth at first visit.
Fig. 4. Panoramic radiograph.
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exposure. It seems to be impossible to stop or alter immu-
nosuppressant regimen in this case. Therefore, consultation 
to his physician should be needed to consider whether a 
different CCB can be substituted for felodipine, or more fa-
vorably substitution can be made by a structurally different 
antihypertensive drug.
The clinician should also emphasize oral hygiene as the 
first step in the treatment of DIGO, because good oral hy-
giene and adequate plaque control decreases the degree of 
the DIGO and improves overall gingival health. Also, fre-
quent supportive periodontal therapy may help in prevent-
ing or retarding the recurrence of DIGO in surgically treated 
cases.13) Furthermore, adjunctive use of chlorhexidine has 
been found to be beneficial in decreasing the severity of 
DIGO.14) Antibiotics can also be used, and in resistant cases 
a surgical therapy such as gingivectomy or periodontal flap 
may be performed, although the condition tends to recur.13) 
Alternative treatment options may include folic acid sup-
plementation. According to the unifying hypothesis, DIGO 
may be secondary to a localized folic acid deficiency. There 
is evidence that topical administration of folic acid may be 
efficacious to decrease the incidence and severity of DIGO.15) 
Gingival overgrowth-inducing drugs among immunosup-
pressant, anticonvulsant, and CCB categories are being up-
dated. It is important to be aware of these newer drugs and 
relationship between the drugs under concomitant or previ-
ous medications. 
Findings point to the importance of comprehensive treat-
ment and cooperation between dentists and physicians 
in the maintenance of the patients under these regimens. 
Clinicians should first consider the nonsurgical therapy, in-
cluding the removal of local factors and substitution of the 
offending drug. If the nonsurgical approach is not effective, 
periodontal surgery can effectively reduce the DIGO. 
Dentists need to be aware of drugs that induce gingival 
overgrowth, the possibility of DIGO, and risk factors, and 
also prevent the progression of DIGO by early detection, 
consultation about the drug change, and the maintenance 
of strict dental hygiene regimes.
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